LivaNova plc (LIVN): שווי פעילות לרווח לפני ריבית, מסים ופחת

LivaNova PLC enjoys global recognition for its development of neurostimulators and cardiac equipment, leveraging an expansion strategy for vagus nerve stimulation systems. Tracking the business's EV/EBITDA multiple history on GURU.Markets, we note that the 16.21 level reflects the current state of the parameter. High barriers to entry are sustained by FDA patents and the unwavering trust of surgeons in the brand's clinical outcomes.

This ratio correlates the total enterprise value, including net debt, with operating profit before depreciation and amortization, allowing for an assessment of the asset's real value regardless of the tax burden. The current EV/EBITDA value for the heavy business segment stands at 16.21, which, combined with full capacity utilization at LivaNova PLC (LIVN) plants and the modernization of production lines, confirms the efficiency of cash flow generation despite high capital intensity.